Brief: 3D Medicines Updates On Strategic Cooperation Agreement
02/07/2025 02:44
July 2 (Reuters) - 3D Medicines Inc 1244.HK: CO AND ITS UNITS AGREE TO PAY CONSIDERATION TO QINGDAO HAINUO OF RMB98.0 MILLION UNDER STRATEGIC COOPERATION AGREEMENT Further company coverage: 1244.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on 3D Medicines
See all newsBrief: 3D Medicines Inc Says Envafolimab Supplemental Application Accepted By NMPA
Brief: 3D Medicines Inc Says Zhang Jing Resigns As CFO
Brief: 3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted
Brief: 3D Medicines Says Envafoimab Granted Orphan Drug Designation
Brief: 3D Medicines Inc Enters Strategic Agreement With Catug Biotechnology